HEPATITIS C VIRUS (HCV) ANTIBODY (ELISA/CLIA)

The Hepatitis C Virus (HCV) Antibody Test (ELISA/CLIA) is a laboratory blood test used to detect antibodies against the Hepatitis C Virus (HCV). It is the primary screening test recommended for identifying individuals who have been exposed to hepatitis C. The test determines whether the immune system has produced antibodies in response to HCV infection.

Hepatitis C is a viral infection that primarily affects the liver. It spreads through contact with infected blood, including unsafe injections, sharing contaminated needles, unscreened blood transfusions, organ transplantation before routine HCV screening, and occupational exposure to infected blood. Although less common, transmission can also occur through sexual contact and from mother to baby during childbirth.

Many people with hepatitis C have no symptoms, particularly during the early stages of infection. When symptoms do occur, they may include fatigue, loss of appetite, nausea, abdominal pain, dark urine, jaundice (yellowing of the skin and eyes), and abnormal liver function tests. Without early diagnosis and treatment, chronic hepatitis C can lead to cirrhosis, liver failure, and hepatocellular carcinoma (liver cancer).

The HCV Antibody Test is performed using advanced ELISA (Enzyme-Linked Immunosorbent Assay) or CLIA (Chemiluminescent Immunoassay) technology, both of which provide excellent sensitivity and specificity for detecting anti-HCV antibodies.

It is important to understand that a positive HCV antibody result indicates previous exposure to the virus but does not confirm an active infection. Some individuals naturally clear the virus without treatment, while others develop chronic infection. Therefore, all positive HCV antibody results should be followed by an HCV RNA (PCR) test to determine whether the virus is currently present in the blood.

Doctors commonly recommend the HCV Antibody Test for individuals with risk factors for hepatitis C, abnormal liver function tests, chronic liver disease, healthcare workers after occupational exposure, blood donors, pregnant women in selected situations, and individuals born during high-risk periods or belonging to high-risk populations.

Benefits of the Test

• Primary screening test for hepatitis C infection.
• Detects antibodies against HCV.
• Supports early identification of HCV exposure.
• Helps identify individuals requiring confirmatory testing.
• Performed using highly sensitive ELISA or CLIA technology.
• Requires only a simple blood sample.
• Useful for routine health screening and blood donor evaluation.
• Supports early diagnosis and treatment planning.

Why Doctors Recommend This Test

Doctors recommend the HCV Antibody Test for hepatitis C screening, evaluation of abnormal liver function tests, assessment of individuals with risk factors for HCV exposure, and routine health screening. Positive results are confirmed using HCV RNA (PCR) testing.

Preparation Before the Test

No special preparation is required.

You may eat and drink normally unless instructed otherwise by your healthcare provider. Inform your doctor about previous hepatitis C infection, liver disease, medications, blood transfusions, or possible exposure to HCV. A blood sample is collected from a vein for laboratory analysis.

Normal Reporting Time

Typically: 1–3 Working Days

Reporting time may vary depending on laboratory methodology.

Who Should Take This Test?

This test is recommended for:

• Individuals with risk factors for hepatitis C.
• Patients with abnormal liver function tests.
• People who received blood transfusions before routine HCV screening.
• Individuals who inject drugs.
• Healthcare workers after occupational exposure.
• Patients with chronic liver disease.
• Organ transplant recipients.
• Blood donors.
• Individuals undergoing routine hepatitis screening.
• Anyone advised by their healthcare provider.